Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darbepoetin alfa vs ESA in chronic kidney disease-related anemia (real-world cohort)
ChiCTR2200057105Phase 4Not yet recruiting
- Sponsor
- Shenzhen Second People's Hospital
- Start
- Jun 2022
- Modality
- Erythropoietins → Hormones & Growth Factors → Recombinant Proteins and Enzymes, Interleukins → Cytokines & Interferons → Recombinant Proteins and Enzymes, Colony Stimulating Factors → Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of darbepoetin alfa in chronic kidney disease (CKD) and anaemia (2 cohorts), sponsored by Shenzhen Second People's Hospital. Primary endpoint: Hemoglobin. Planned start Jun 2022; status: not yet recruiting.
02
Drugs
darbepoetin alfa
03
Conditions
chronic kidney disease (CKD)anaemia
Beyond the preview
Go deeper on ChiCTR2200057105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200057105.